Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.

Abstract: The present invention provides a method for preventing and/or treating a NSAID-induced gastric ulcer. The method comprises administrating an effective amount of a lactic acid bacterium set to a subject. The lactic acid bacterium set comprises Lactobacillus plantarum GKD7 and Pediococcus acidilactici GKA4.

Abstract: The present invention provides an active substance of Morchella, its use and a composition thereof for improving disturbance of reproductive function, especially, for manufacturing a pharmaceutical composition to improve disturbance of reproductive function induced by obesity or metabolic syndrome. The composition with the active substance of Morchella can effectively improve the structural integrity of testicular tissues and sperm, increase testosterone levels in the blood, and reduce the oxidation stress in sperms.

Abstract: The present invention is related to an active substance of Hericium erinaceus having a pain-relieving effect, and a pharmaceutical composition including the active substance. The active substance is prepared using the following steps: (a) inoculating a mycelium of H. erinaceus on an agar plate and incubating at 15-32° C. for 8-16 days; (b) inoculating the incubated H. erinaceus mycelia from step (a) into a medium in a flask and incubating at 20-30° C. and pH 4.5-6.5 for 3-5 days; (c) inoculating the incubated H. erinaceus mycelia from step (b) into a medium in a fermentation tank and incubating at 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the H. erinaceus mycelia; and (d) desiccating the fermented medium of the H. erinaceus mycelia from step (c) to obtain the powder of the H. erinaceus mycelia, which is further purified and isolated to obtain a novel compound of H. erinaceus.

Abstract: The present invention provides a Bifidobacterium lactis GKK2, a composition comprising thereof and its use for improving asthma, especially for lowering airway resistance, reducing levels of non-specific and specific IgE in serum, alleviating bronchoconstriction and increasing levels of GSH reductase in liver tissue interstitial fluid to improve allergic asthma.

Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.

Abstract: The present invention provides a novel use of Morchella active substance. The Morchella active substance is for manufacturing a composition for ameliorating Sarcopenia. The preparation method of the Morchella active substance comprises the following steps: (a) culturing Morchella mycelium in a plate media between 15° C. and 30° C. for 1 to 2 weeks; (b) inoculating the Morchella mycelium cultured in step (a) to a flask and culturing the Morchella mycelium between 15° C. and 30° C. with a pH of 2 to 6 for 4 to 7 days; and (c) inoculating the Morchella mycelium cultured in step (b) to a fermentation tank and culturing the Morchella mycelium between 15° C. and 30° C. with a pH of 2 to 6 for 6 to 10 days, so as to obtain a Morchella mycelium fermentation broth containing the Morchella active substance.

Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.

Abstract: The present invention discloses uses of treating, preventing or improving bone diseases by Lactobacillus or a composition including the Lactobacillus. The Lactobacillus and compositions can increase the blood calcium concentration, the trabecular bone volume density, the trabecular thickness, the trabecular number and the bone mineral density of a subject, and reduce trabecular spacing of the subject. Further, the present invention discloses a method for treating a subject diagnosed with a bone disease, through identifying the subject having the bone disease and administering to the subject an effective amount of a composition including at least one of Lactobacillus plantarum GKM3 and Lactobacillus paracasei GKS6, wherein the Lactobacillus plantarum GKM3 is deposited in China General Microbiological Culture Collection Center (CGMCC) with a deposition number of CGMCC 14565 on Aug. 25, 2017, and the Lactobacillus paracasei GKS6 is deposited in CGMCC with a deposition number of CGMCC 14566 on Aug. 25, 2017.

Abstract: The present invention provides an active substance of Morchella, its use and a composition thereof for improving disturbance of reproductive function, especially, for manufacturing a pharmaceutical composition to improve disturbance of reproductive function induced by obesity or metabolic syndrome. The composition with the active substance of Morchella can effectively improve the structural integrity of testicular tissues and sperm, increase testosterone levels in the blood, and reduce the oxidation stress in sperms.

Abstract: The present invention provides an active substance of Morchella, its use and a composition thereof for improving disturbance of reproductive function, especially, for manufacturing a pharmaceutical composition to improve disturbance of reproductive function induced by obesity or metabolic syndrome. The composition with the active substance of Morchella can effectively improve the structural integrity of testicular tissues and sperm, increase testosterone levels in the blood, and reduce the oxidation stress in sperms.

Abstract: A method of preparing Cordyceps cicadae mycelium active substances for preventing and/or treating xerophthalmia is provided. The method comprises: (a) culturing a Cordyceps cicadae mycelium in a plate media at 15 to 35° C. for 5 to 14 days; (b) inoculating the mycelium of step (a) to a flask containing liquid media and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days; (c) inoculating the mycelium of step (b) to a fermenter tank and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid; (d) freeze-drying and grating the fermentation liquid, so as to obtain a Cordyceps cicadae mycelium powder; (e) extracting the powder with solvent, so as to obtain a Cordyceps cicadae mycelium extract; and (f) drying the extract, so as to obtained the Cordyceps cicadae mycelium active substances.

Abstract: The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35° C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35° C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35° C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.

Abstract: The present invention is related to an active substance of Hericium erinaceus having a pain-relieving effect, and a pharmaceutical composition including the active substance. The active substance is prepared using the following steps: (a) inoculating a mycelium of H. erinaceus on an agar plate and incubating at 15-32° C. for 8-16 days; (b) inoculating the incubated H. erinaceus mycelia from step (a) into a medium in a flask and incubating at 20-30° C. and pH 4.5-6.5 for 3-5 days; (c) inoculating the incubated H. erinaceus mycelia from step (b) into a medium in a fermentation tank and incubating at 24-32° C. and pH 4.5-5.5 for 8-16 days to obtain a fermented medium of the H. erinaceus mycelia; and (d) desiccating the fermented medium of the H. erinaceus mycelia from step (c) to obtain the powder of the H. erinaceus mycelia, which is further purified and isolated to obtain a novel compound of H. erinaceus.

Abstract: The present invention provides a method for preventing, postponing or treating ocular diseases, including changes in the anterior/posterior chamber volume, vitreous humour, and/or retinal detachment. The method comprises administering to a subject an effective amount of Cordyceps cicadae mycelium active substances. A method for preparing Cordyceps cicadae mycelium active substances comprises following steps: (a) culturing a Cordyceps cicadae mycelium on a plate medium between 15-35° C. for 5-14 days; (b) inoculating the Cordyceps cicadae mycelium of step (a) into a flask and culturing the mycelium between 15-35° C. and pH 2-8 for 3-7 days; and (c) inoculating the Cordyceps cicadae mycelium of step (b) into a fermenter tank and culturing the mycelium by stirring between 15-35° C. and pH 2-8 for 3-5 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquid containing the Cordyceps cicadae mycelium active substances.

Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.

Abstract: The present invention provides a Bifidobacterium lactis GKK2, a composition comprising thereof and its use for improving asthma, especially for lowering airway resistance, reducing levels of non-specific and specific IgE in serum, alleviating bronchoconstriction and increasing levels of GSH reductase in liver tissue interstitial fluid to improve allergic asthma.

Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.

Abstract: The present invention discloses uses of treating, preventing or improving bone diseases by Lactobacillus or a composition including the Lactobacillus. The Lactobacillus and compositions can increase the blood calcium concentration, the trabecular bone volume density (BV/TV ratio), the trabecular thickness (Tb.Th), the trabecular number (Tb.N) and the bone mineral density (BMD) of a subject, and reduce trabecular spacing (Tb.Sp) of the subject. Further, the present invention discloses a method for treating a subject diagnosed with a bone disease, comprises steps of identifying the subject having the bone disease, and administering to the subject an effective amount of a composition including at least one of Lactobacillus plantarum GKM3 and Lactobacillus paracasei GKS6, wherein the Lactobacillus plantarum GKM3 is deposited in China General Microbiological Culture Collection Center (CGMCC) with a deposition number of CGMCC 14565 on Aug.

Abstract: The present invention discloses the active substances for preventing hearing deterioration, its preparation method, the pharmaceutical composition containing the active substances, and the preparation method of the pharmaceutical composition. The preparation method of the active substances is performed by plate cultivation, flask cultivation and fermentation tank cultivation, to obtain the active substances of Hericium erinaceus mycelia in powder form. The powder of H. erinaceus mycelia is proved to have the effect of preventing hearing deterioration.